GoodRx Holdings

GoodRx Holdings, Inc. operates a consumer-focused digital healthcare platform. The firm offers information and tools to help consumers compare prices for prescription drugs. It operates applications and websites that provide prices and discounts at local and mail-order pharmacies. The company was founded by in Trevor Bezdek and Douglas Hirsch Joseph in September 2015 and is headquartered in Santa Monica, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

GoodRx reports Q4 revenue decline but anticipates growth opportunities

GoodRx's Q4 2022 performance showed a decline in revenue but improvements in adjusted EBITDA. The company's focus on deepening relationships, increasing savings, and leveraging data presents strengths. Challenges include financial impacts from the grocer issue and decisions on revenue streams. Opportunities lie in non-grocery retailers, pharma manufacturer solutions, and sales optimization.

GoodRx reports strong Q1 performance and anticipates growth opportunities

GoodRx's Q1 performance reflects growth and positive outlook for managed solutions segment, despite challenges in revenue moderation and deal timelines.
The company's strengths lie in its strong foundation, talented team, and unique marketplace value proposition, with opportunities for further growth and innovation.
Challenges include potential revenue impact from program moderation and deal delays, but regulatory proposals are not expected to significantly affect business operations.
Overall, GoodRx remains focused on driving volume growth, maintaining market leadership, and providing affordable prescriptions to consumers.

GoodRx exceeds Q2 guidance, focuses on growth and partnerships

GoodRx's Q2 2023 earnings call showcased strong financial performance, exceeding guidance and reporting net income driven by a release of valuation allowance.
The company's focus on growth, profitability, and strategic realignment positions it well for compounding growth in 2024 and beyond, emphasizing proactive retail partnerships and efficient customer service strategies.
While challenges in deprioritizing certain solutions and balancing marketing spend efficiency exist, opportunities in optimizing retailer partnerships, leveraging data analytics, and attracting new members without incremental spend are key for future success.
Overall, GoodRx's innovative approach, unique value proposition, and financial and operational strengths highlight its resilience and potential for sustained growth and profitability.

GoodRx reports revenue growth and eyes pharma solutions expansion

GoodRx reported solid Q3 performance with revenue growth and strong cash generation, focusing on margin improvement and bottom-line profitability.
Despite challenges in subscription revenue and one-time payments, the company is eyeing growth opportunities in ISP, pharma solutions, and marketing efforts.
Analyst questions addressed key areas like retail stability, revenue growth expectations, and margin dynamics, indicating investor interest in future prospects.
GoodRx's strategic focus on expanding services, enhancing pricing strategies, and market access programs positions it for continued growth and value creation.

GoodRx exceeds Q4 expectations, eyes growth through strategic initiatives

GoodRx's Q4 '23 performance reflects strong financials, operational resilience, and strategic focus on growth initiatives.
The company's success in saving consumers billions and expanding market reach positions it well for future opportunities.
Challenges such as system issues and market competition require ongoing attention and strategic planning.
Opportunities in scaling solutions, targeted marketing, and strategic partnerships can drive sustained growth and market leadership.

GoodRx reports solid Q1 performance, eyes margin expansion opportunities

GoodRx's Q1 2024 performance showcased revenue growth and strong EBITDA margins, supported by strategic capital deployment and cash reserves.
Challenges include PTR per MAC decline and addressing analyst inquiries on ISP growth and margin concerns.
Opportunities lie in upcoming Analyst Day insights, ISP performance enhancements, and driving margin expansion through operational efficiencies.
Overall, GoodRx anticipates sustained growth, margin improvement, and continued ISP expansion throughout the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

ICON

Investors looking for stocks in the Medical Services sector might want to consider either Icon PLC (ICLR) or GoodRx Holdings, Inc. (GDRX). But which of these two companies is the best option for those looking for undervalued stocks?

ICLR or GDRX: Which Is the Better Value Stock Right Now?

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx is a leading resource for people with diabetes to find prescription savings and information, having helped almost 2.5 million Americans save more than $500 million on diabetes treatments to date. By offering invaluable access to affordable diabetes medicines and glucose monitors, accurate and digestible information about treatment options, and thorough research on diabetes and insulin prices, GoodRx is making it easier for people to afford their med.

GoodRx Surpasses $500 Million in Savings For Diabetic Americans

While the top- and bottom-line numbers for GoodRx Holdings, Inc. (GDRX) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

GoodRx Holdings, Inc. (GDRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.06 per share a year ago.

GoodRx Holdings, Inc. (GDRX) Beats Q2 Earnings and Revenue Estimates

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), a leading resource for healthcare savings and information, has released its financial results for the second quarter 2023. Second Quarter 2023 Highlights Total revenue of $189.7 million, exceeding previously announced guidance Net income of $58.8 million1; Net income margin of 31.0% Adjusted Net Income2 of $28.4 million; Adjusted Net Income Margin2 of 15.0% Adjusted EBITDA2 of $53.5 million;.

GoodRx Reports Second Quarter 2023 Results

When GoodRx Holdings, Inc. NASDAQ: GDRX burst onto the scene in the middle of the pandemic, it brought promises of saving Americans money on their drug prescriptions. While consumers have indeed seen billions of dollars in savings, shareholders have seen nothing but losses.

More Good News Coming? GoodRx Spikes Ahead of Q2 Earnings

Aurora Innovation

BGC Group Inc

Genworth Financial

Hecla Mining

Joby Aviation

Nikola

Opendoor

Transocean

Rocket Lab USA

Roivant Sciences Ltd

Investors are even willing to dip into the cheap-stock territory outside the S&P 500 — and it's paying off handsomely so far.

11 Revived Stocks That Traded For $5 Or Less Are Now Worth Billions

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced Medicine Cabinet, a comprehensive solution designed to help consumers seamlessly manage their medications. Medicine Cabinet gives people easy-to-use tools to keep track of their prescriptions, get refill and daily pill reminders, find low prices, and earn rewards for staying on track. By making prescription management easier, smarter and more relevant, Medicin.

GoodRx Unveils Medicine Cabinet, A Better Way To Manage All Of Your Prescriptions

I recommended a hold until there are clearer signs of growth inflection in FY24, despite strong Q1 results. GoodRx Holdings is making strategic moves to strengthen direct connections with retail pharmacies, potentially boosting margins, but may strain relationships with Pharmacy Benefit Managers. Caution is advised for FY23 due to less-than-expected guidance, potential margin compression, and the shift in business model which may affect revenues.

GoodRx Holdings: Stay Cautious In FY23 Until Clear Signs Of Growth Inflection Appear

GoodRx offers a digital prescription platform. CVS Caremark is the nation's largest pharmacy benefits manager.

Why Shares of GoodRx Holdings Climbed This Week

GoodRx Holdings, Inc. (GDRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

GoodRx Holdings, Inc. (GDRX) Soars 21.5%: Is Further Upside Left in the Stock?

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), a leading resource for healthcare savings and information, today announced it will release its second quarter 2023 financial results before U.S. markets open on Wednesday, August 9, 2023. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the confer.

GoodRx Announces Date for Second Quarter 2023 Earnings Release and Conference Call

CVS Health

GoodRx, a leading prescription discount platform, has announced a new partnership with CVS Health Corp (NYSE:CVS)'s Caremark, a major pharmacy benefits manager (PBM). The collaboration will introduce a new product called Caremark Cost Saver, which aims to help commercially insured customers save on generic drugs at eligible pharmacies.

GoodRx surges on partnership with CVS's Caremark to help customers save on prescription drugs

CVS Health's Caremark pharmacy benefit management (PBM) company and the drug discount app GoodRx are launching a service they hope will lower drug costs for commercial

CVS Health's PBM And GoodRx Partner On Drug Discount Program For Commercially Insured Customers

GoodRx GDRX, -1.64% shares gained 3.5% premarket on Wednesday after the drug-savings app provider and CVS Health CVS, +2.75% announced a new program to lower out-of-pocket prescription drug costs for CVS Caremark clients' members. CVS Caremark eligible members will have automatic access to GoodRx prescription pricing, potentially generating savings on generic medications at the pharmacy counter, the companies said in a release Wednesday.

GoodRx shares gain on new prescription-drug discount program with CVS

Prescription drug discount solution to help lower costs, improve experience for tens of millions of CVS Caremark clients' members WOONSOCKET, R.I., and SANTA MONICA, Calif.

CVS Caremark and GoodRx to launch Caremark® Cost Saver™ to help lower out-of-pocket drug costs for CVS Caremark clients' members

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), a leading resource for healthcare savings and information, today announced the appointment of Dorothy Gemmell as Chief Commercial Officer, effective July 3, 2023. Gemmell will work closely with Aaron Crittenden, newly appointed Chief Revenue Officer, and together they will lead the company's Pharma Manufacturer Solutions business, which provides solutions for pharmaceutical and medical device companies. Gemmell brings with her a stro.

GoodRx Appoints Dorothy Gemmell as Chief Commercial Officer

The company's integrated pharmaceutical platform, accretive growth through disciplined M&A, and undervaluation lead to a 'buy' rating. With a fair value of $6.30, averaged between my DCF and Alpha Spread's relative valuation, the stock is undervalued by 9%. GoodRx's value proposition relies on network-effect-driven scale and integrative growth, with its acquisition of VitaCare and expansion into multiple consumer-facing verticals.

GoodRx's Integrative Growth Strategy Inches Towards Sustained Profitability

GoodRx, the prescription-drug savings company, has seen a ~20% jump this year, with growing active consumers and a budding subscription plan. The company has diversified its revenue streams through subscription plans, online health content, telemedicine, and pharmacy services, and maintains adjusted EBITDA margins in the mid-20s. However, risks include a pivot to direct relationships with retail pharmacies and a recent FTC scuffle that may damage the brand.

GoodRx: New Leadership May Set Up This Struggling Company For Success

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading digital healthcare platform, today announced that executives from the Company will be presenting at the Jefferies Healthcare Conference in New York, NY on Thursday, June 8, 2023 at 12:30 p.m. Pacific Time (3:30 p.m. Eastern Time). A live webcast of the presentation will be available on the Company's Investor Relations website, https://investors.goodrx.com/. Following the conference, an archived recording will.

GoodRx to Present at the Jefferies Healthcare Conference

While the top- and bottom-line numbers for GoodRx Holdings, Inc. (GDRX) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

GoodRx Holdings, Inc. (GDRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.10 per share a year ago.

GoodRx Holdings, Inc. (GDRX) Tops Q1 Earnings and Revenue Estimates

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), a leading digital healthcare platform, has released its financial results for the first quarter 2023. First Quarter 2023 Highlights Total revenue of $184.0 million, exceeding previously announced guidance Net loss of $3.3 million1; Net loss margin of 1.8% Adjusted Net Income2 of $29.5 million; Adjusted Net Income Margin2 of 16.0% Adjusted EBITDA2 of $53.2 million; Adjusted EBITDA Margin2 of.

GoodRx Reports First Quarter 2023 Results

Medicine is a serious business, as is saving on medicine. For that reason, we present the PYMNTS Provider Rankings of Prescription Apps monthly to gauge the apps helping consumers afford pricey remedies.

GoodRx Reigns Again On the Provider Rankings of Prescription Apps

GoodRx is scheduled to report first-quarter earnings on May 10. The digital platform offers prescription drug discounts.

News for GoodRx Holdings Stock (GDRX)